Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
9.14
-0.10 (-1.08%)
May 14, 2026, 9:44 AM EDT - Market open
Ocular Therapeutix Stock Forecast
Stock Price Forecast
The 10 analysts that cover Ocular Therapeutix stock have a consensus rating of "Strong Buy" and an average price target of $24.2, which forecasts a 164.77% increase in the stock price over the next year. The lowest target is $18 and the highest is $31.
Price Target: $24.2 (+164.77%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ocular Therapeutix stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 4 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 11 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $30 | Buy | Reiterates | $30 | +228.23% | May 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +129.76% | Apr 13, 2026 |
| Clear Street | Clear Street | Strong Buy Maintains $21 → $28 | Strong Buy | Maintains | $21 → $28 | +206.35% | Mar 3, 2026 |
| Needham | Needham | Strong Buy Maintains $20 → $18 | Strong Buy | Maintains | $20 → $18 | +96.94% | Feb 20, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +129.76% | Feb 18, 2026 |
Financial Forecast
Revenue This Year
56.07M
from 51.95M
Increased by 7.93%
Revenue Next Year
109.94M
from 56.07M
Increased by 96.07%
EPS This Year
-1.36
from -1.42
EPS Next Year
-1.33
from -1.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 62.0M | 290.9M | ||||||
| Avg | 56.1M | 109.9M | ||||||
| Low | 51.0M | 51.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 19.2% | 418.7% | ||||||
| Avg | 7.9% | 96.1% | ||||||
| Low | -1.9% | -7.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.13 | -0.58 | ||||||
| Avg | -1.36 | -1.33 | ||||||
| Low | -1.68 | -1.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.